The $94 Million Question Mark
In 2018, Sangamo Therapeutics watched their stock price crater 27% in a single day. Their zinc finger nuclease therapy for Hunter syndrome had failed its Phase III trial. Not “showed modest improvement” failed. Not “needs optimization” failed. Complete, unequivocal failure.
The financial headlines screamed about biotech bubbles and overhyped gene editing. But buried in the 847-page clinical trial report was something far more valuable than a successful drug: a brutal lesson in why human genetics refuses to behave like a textbook. The failure taught researchers that editing a single gene in a complex metabolic pathway is like trying to fix a symphony by retuning one violin.
When Designer Babies Became Cautionary Tales
He Jiankui’s 2018 announcement that he had edited CCR5 genes in twin embryos sent shockwaves through the scientific community. The immediate outrage focused on ethics, but the deeper problem was scientific hubris masquerading as precision medicine. He had targeted a gene variant that provides HIV resistance in roughly 1% of Northern Europeans, then applied this edit to Chinese embryos where the protective effect was completely unproven.
The twins, known as Lulu and Nana, likely gained no meaningful protection against HIV while potentially facing increased susceptibility to West Nile virus and influenza. Population genetics data from the 1000 Genomes Project had been sitting in public databases for years, showing that CCR5 variants behave differently across genetic backgrounds. He either ignored this data or never looked.
This wasn’t just rogue science. It was bad science. The failure showed how genomic context matters more than individual gene function. A “beneficial” edit in one population can become neutral or harmful in another, depending on what other genetic variants are present.
The Huntington’s Paradox
Wave Life Sciences spent eight years developing antisense oligonucleotides to treat Huntington’s disease. Their approach seemed bulletproof: target the mutant huntingtin gene while leaving the normal copy alone. In 2021, their lead candidate failed Phase Ib trials so spectacularly that they terminated the entire Huntington’s program.
The problem wasn’t the technology. Antisense oligonucleotides work beautifully in spinal muscular atrophy, earning FDA approval for Spinraza in 2016. The issue was assuming that reducing mutant huntingtin protein would automatically improve symptoms. Instead, patients showed no clinical benefit despite significant protein reduction.
Post-mortem analysis exposed the harsh reality of neurodegeneration: by the time symptoms appear, too much damage has already occurred. The brain had been accumulating toxic protein aggregates for decades. Reducing new protein production was like stopping gasoline delivery to a house that’s already burning. This failure reshaped the entire field’s timeline expectations and pushed researchers toward much earlier intervention strategies.
Why Failure Accelerates Discovery
These spectacular failures accomplished something that successful trials rarely do: they forced researchers to confront the gap between genomic theory and biological reality. The Human Genome Project promised that knowing our genetic code would unlock therapeutic possibilities. Twenty years later, we’re learning that genes exist in networks, not isolation.
Sangamo’s failure led to combination therapy approaches that target multiple points in metabolic pathways simultaneously. Companies like Denali Therapeutics now develop platform technologies that can deliver multiple therapeutic payloads to specific cell types, rather than betting everything on single-gene fixes.
The He Jiankui controversy sparked international governance frameworks for heritable genome editing. More importantly, it accelerated research into polygenic risk scores and population-specific genetic effects. Companies like 23andMe now routinely adjust their health reports based on genetic ancestry, something unthinkable before this cautionary tale.
The New Genomics Playbook
Modern genomics companies are building failure into their development strategies. Vertex Pharmaceuticals runs parallel programs targeting the same disease through different mechanisms. When their first cystic fibrosis drug worked for only 4% of patients, they had backup compounds in development that eventually covered 90% of cases.
The field has also embraced “smart failures” through adaptive trial designs. Instead of running one massive Phase III trial, companies like Moderna run smaller studies with built-in decision points. Their COVID-19 vaccine program included over 30 different formulations tested in parallel, with most failing early and cheaply.
Computational approaches now predict failure modes before they reach patients. AlphaFold’s protein structure predictions help identify why certain gene therapies might fail based on target accessibility. Population genetics databases like gnomAD reveal rare variants that could interfere with therapeutic designs across different ethnic groups.
The next wave of genomic medicine won’t promise miraculous single-gene cures. Instead, it will offer precise, population-tailored interventions backed by decades of hard-won lessons. Perhaps the most profound truth is that science advances not despite failure, but because of it.